About Akribion Therapeutics
Akribion Therapeutics is a company based in Zwingenberg (Germany) founded in 2024 by Michael Krohn, Paul Scholz, and Lukas Linnig.. Akribion Therapeutics has raised $8.2 million across 1 funding round from investors including Bruker, MP Beteiligung and CARMA FUND. Akribion Therapeutics offers products and services including G-dase E payload. Akribion Therapeutics operates in a competitive market with competitors including Rakuten Medical, miRecule and GritBIO, among others.
- Headquarter Zwingenberg, Germany
- Founders Michael Krohn, Paul Scholz, Lukas Linnig
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Akribion Therapeutics Gmbh
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$8.2 M (USD)
in 1 rounds
-
Latest Funding Round
$8.2 M (USD), Seed
Feb 04, 2025
-
Investors
Bruker
& 5 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Akribion Therapeutics
Akribion Therapeutics offers a comprehensive portfolio of products and services, including G-dase E payload. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
RNA-guided nuclease for targeted cell depletion in cancer.
Unlock access to complete
Unlock access to complete
Funding Insights of Akribion Therapeutics
Akribion Therapeutics has successfully raised a total of $8.2M through 1 strategic funding round. The most recent funding activity was a Seed round of $8.2 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $8.2M
-
First Round
First Round
(04 Feb 2025)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2025 | Amount | Seed - Akribion Therapeutics | Valuation | CARMA FUND , RV Invest |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Akribion Therapeutics
Akribion Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Bruker, MP Beteiligung and CARMA FUND. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are provided for life science and healthcare innovations.
|
Founded Year | Domain | Location | |
|
RV Invest is engaged in funding biotech innovations.
|
Founded Year | Domain | Location | |
|
Early-stage investments are made in high-tech startups by HTGF.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Akribion Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Akribion Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Akribion Therapeutics Comparisons
Competitors of Akribion Therapeutics
Akribion Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rakuten Medical, miRecule and GritBIO, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Photoimmunotherapy platform for precision cancer treatment is developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA therapies for cancer treatment are developed using genomic data.
|
|
| domain | founded_year | HQ Location |
Develops innovative therapeutic technologies for cancer treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Akribion Therapeutics
Frequently Asked Questions about Akribion Therapeutics
When was Akribion Therapeutics founded?
Akribion Therapeutics was founded in 2024 and raised its 1st funding round 1 year after it was founded.
Where is Akribion Therapeutics located?
Akribion Therapeutics is headquartered in Zwingenberg, Germany. It is registered at Zwingenberg, Hesse, Germany.
Who is the current CEO of Akribion Therapeutics?
Michael Krohn is the current CEO of Akribion Therapeutics. They have also founded this company.
Is Akribion Therapeutics a funded company?
Akribion Therapeutics is a funded company, having raised a total of $8.2M across 1 funding round to date. The company's 1st funding round was a Seed of $8.2M, raised on Feb 04, 2025.
What does Akribion Therapeutics do?
Developer of RNA-guided technology with applications in cancer therapy and other indications. It offers RNA-guided nuclease-based technology for programmable cell depletion using its G-dase E payload by targeting HPV-induced Oropharyngeal Head and Neck Cancer.
Who are the top competitors of Akribion Therapeutics?
Akribion Therapeutics's top competitors include Rakuten Medical, miRecule and GritBIO.
What products or services does Akribion Therapeutics offer?
Akribion Therapeutics offers G-dase E payload.
Who are Akribion Therapeutics's investors?
Akribion Therapeutics has 6 investors. Key investors include Bruker, MP Beteiligung, CARMA FUND, RV Invest, and Hessen Kapital.